Floatz logo

DEXAMETHASONE

Acinar Cell Adenocarcinoma of the Pancreas

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Acinar Cell Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
Eloxatin
Yale University
Phase 2BBB
FLUOROURACILUM
Yale University
Phase 2BBB
Irinotecan
Artios Pharma Ltd
Phase 2BB
Calcium folinate pentahydrate
Yale University
Phase 2BB
Metformin
Case Comprehensive Cancer Center
Phase 2BB

View all 30 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →